Entry

D11894                      Drug

Name

Amivantamab (USAN/INN);
Amivantamab (genetical recombination) (JAN);
Amivantamab-vmjw;
Rybrevant (TN)

Product

RYBREVANT (Janssen Biotech)

Formula

C6472H10014N1730O2023S46

Exact mass

145810.1054

Mol weight

145900.1288

Sequence

(A chain)
QVQLVESGGG VVQPGRSLRL SCAASGFTFS TYGMHWVRQA PGKGLEWVAV IWDDGSYKYY
GDSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCARDG ITMVRGVMKD YFDYWGQGTL
VTVSSASTKG PSVFPLAPSS KSTSGGTAAL GCLVKDYFPE PVTVSWNSGA LTSGVHTFPA
VLQSSGLYSL SSVVTVPSSS LGTQTYICNV NHKPSNTKVD KRVEPKSCDK THTCPPCPAP
ELLGGPSVFL FPPKPKDTLM ISRTPEVTCV VVDVSHEDPE VKFNWYVDGV EVHNAKTKPR
EEQYNSTYRV VSVLTVLHQD WLNGKEYKCK VSNKALPAPI EKTISKAKGQ PREPQVYTLP
PSREEMTKNQ VSLTCLVKGF YPSDIAVEWE SNGQPENNYK TTPPVLDSDG SFLLYSKLTV
DKSRWQQGNV FSCSVMHEAL HNHYTQKSLS LSPGK
(B chain)
QVQLVQSGAE VKKPGASVKV SCETSGYTFT SYGISWVRQA PGHGLEWMGW ISAYNGYTNY
AQKLQGRVTM TTDTSTSTAY MELRSLRSDD TAVYYCARDL RGTNYFDYWG QGTLVTVSSA
STKGPSVFPL APSSKSTSGG TAALGCLVKD YFPEPVTVSW NSGALTSGVH TFPAVLQSSG
LYSLSSVVTV PSSSLGTQTY ICNVNHKPSN TKVDKRVEPK SCDKTHTCPP CPAPELLGGP
SVFLFPPKPK DTLMISRTPE VTCVVVDVSH EDPEVKFNWY VDGVEVHNAK TKPREEQYNS
TYRVVSVLTV LHQDWLNGKE YKCKVSNKAL PAPIEKTISK AKGQPREPQV YTLPPSREEM
TKNQVSLTCL VKGFYPSDIA VEWESNGQPE NNYKTTPPVL DSDGSFFLYS RLTVDKSRWQ
QGNVFSCSVM HEALHNHYTQ KSLSLSPGK
(C chain)
AIQLTQSPSS LSASVGDRVT ITCRASQDIS SALVWYQQKP GKAPKLLIYD ASSLESGVPS
RFSGSESGTD FTLTISSLQP EDFATYYCQQ FNSYPLTFGG GTKVEIKRTV AAPSVFIFPP
SDEQLKSGTA SVVCLLNNFY PREAKVQWKV DNALQSGNSQ ESVTEQDSKD STYSLSSTLT
LSKADYEKHK VYACEVTHQG LSSPVTKSFN RGEC
(D chain)
DIQMTQSPSS VSASVGDRVT ITCRASQGIS NWLAWFQHKP GKAPKLLIYA ASSLLSGVPS
RFSGSGSGTD FTLTISSLQP EDFATYYCQQ ANSFPITFGQ GTRLEIKRTV AAPSVFIFPP
SDEQLKSGTA SVVCLLNNFY PREAKVQWKV DNALQSGNSQ ESVTEQDSKD STYSLSSTLT
LSKADYEKHK VYACEVTHQG LSSPVTKSFN RGEC
(Disulfide bridge: A22-A96, A152-A208, A228-C214, A234-B228, A237-B231, A269-A329, A375-A433, B22-B96, B146-B202, B222-D214, B263-B323, B369-B427, C23-C88, C134-C194, D23-D88, D134-D194)

Type

Peptide

Class

Antineoplastic
DG01918  Tyrosine kinase inhibitor
  DG01917  Receptor tyrosine kinase inhibitor
   DG03162  EGFR inhibitor

Remark

ATC code:

L01FX18

Product:

D11894<US>

Efficacy

Antineoplastic

Disease

Non-small cell lung cancer (EGFR exon 20 insertion) [DS:H00014]

Comment

Monoclonal antibody; bispecific antibody

Target

EGFR* [HSA_VAR:1956v2] [HSA:1956] [KO:K04361]
EGFR [HSA:1956] [KO:K04361]
MET [HSA:4233] [KO:K05099]

Pathway

hsa04010

MAPK signaling pathway

hsa04014

Ras signaling pathway

hsa04015

Rap1 signaling pathway

hsa04151

PI3K-Akt signaling pathway

hsa04510

Focal adhesion

hsa04520

Adherens junction

hsa05200

Pathways in cancer

Interaction

Brite

Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
  L01 ANTINEOPLASTIC AGENTS
   L01F MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES
    L01FX Other monoclonal antibodies and antibody drug conjugates
     L01FX18 Amivantamab
      D11894  Amivantamab (USAN/INN) <US>
USP drug classification [BR:br08302]
Antineoplastics
  Molecular Target Inhibitors
   Amivantamab
    D11894  Amivantamab (USAN/INN)
Drug groups [BR:br08330]
Antineoplastic
  DG01918  Tyrosine kinase inhibitor
   DG01917  Receptor tyrosine kinase inhibitor
    DG03162  EGFR inhibitor
     D11894  Amivantamab
Drug classes [BR:br08332]
Antineoplastic
  DG03162  EGFR inhibitor
   D11894  Amivantamab
Target-based classification of drugs [BR:br08310]
Protein kinases
  Receptor tyrosine kinases (RTK)
   EGFR family
    EGFR
     D11894  Amivantamab (USAN/INN) <US>
    EGFR* [HSA_VAR:1956v2]
     D11894  Amivantamab (USAN/INN) <US>
   MET family
    MET
     D11894  Amivantamab (USAN/INN) <US>
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
  D11894
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
  D11894
Pharmacogenomic biomarkers [br08341.html]
Somatic variations in targeted cancer therapies
  D11894

Other DBs

CAS:	2171511-58-1